Poster – Pagina 3

Settembre 9, 2023

Image guided thermal ablation of T1 renal cell cancer: A single centre experience.

Image guided thermal ablation of T1 renal cell cancer: A single centre experience. Purpose: To evaluate the oncological outcomes and survival times after ablation of T1 renal cell carcinoma (RCC) in our unit over a 9-year period. Materials and Methods: We retrospectively reviewed all patients with biopsy proven RCC who underwent image guided tumour ablation (IGTA) of a T1 tumour between 1st March 2013 and 1st August 2022. Data collected included: patient demographics, tumour size and histology, pre and post procedure creatinine, ablation technique, complications, oncological outcomes, disease free survival and overall survival. Results: 50 ablative procedures were performed on 46 RCC (mean tumour size 2.6cm) in 45 patients. Technical success was achieved in 100% of tumours (n=46/46). Complications occurred in 8% of procedures (n=4/50). Median clinical follow-up was 27.5 months (range 3 - 88). There was no significant change in creatinine due to IGTA. Primary efficacy of ablation was 94% (43/46 tumours). Microwave ablation (MVA) was less likely to achieve local tumour control when compared to radiofrequency ablation (RFA) (82% (14/17) vs 100% (28/28) respectively, (p=0.02). Larger median RCC diameter was associated with failed primary efficacy in the MWA group (3.8 cm vs 2.4 cm respectively, p= 0.045). Overall survival at 1, 5 and 9 years was 97.4%, 66.7% and 40% respectively. Conclusion: IGTA is a highly efficacious modality and provides an effective durable treatment option for patients with T1 RCCs. Primary efficacy was greater with RFA than MWA. Primary efficacy failure in the MWA group is associated with greater median RCC size.

Settembre 9, 2023

Integrating clinical data with AI to optimise biopsy decisions after prostate MRI

The increased specificity achieved through integrating patient PSAD and radiologists’ PI-RADS scores with AI software can potentially reduce false positive cases, further aiding patient selection for biopsy using MRI.

Settembre 9, 2023

Does PSA density correlate with indicators of clinically significant prostate carcinoma?

...these advantages may warrant the use of PSA density in the clinical decision-making process as an indicator of clinically significant prostate carcinoma alongside other traditional markers...

Settembre 9, 2023

Imaging findings of primary prostatic lymphoma

[1] Wang K, Wang N, Sun J, Fan Y, Chen L. Primary prostate lymphoma: A case report and literature review. Int J Immunopathol Pharmacol. 2019 Jan-Dec;33:2058738419863217. doi: 10.1177/2058738419863217. [2] Taleb A, Ismaili N, Belbaraka R, Bensouda A, Elghissassi I, Elmesbahi O, Droz JP, Errihani H., Primary lymphoma of the prostate treated with rituximab-based chemotherapy: a case report and review of the literature. Cases J. 2009 Aug 11;2:8875. doi: 10.1186/1757-1626-0002-0000008875. [3] Hu S, Wang Y, Yang L, Yi L, Nian Y. Primary non-Hodgkin's lymphoma of the prostate with intractable hematuria: A case report and review of the literature. Oncol Lett. 2015 Mar;9(3):1187-1190. doi: 10.3892/ol.2014.2829. [4] D'souza MM, Jaimini A, Bansal A, Tripathi M, Sharma R, Mondal A, Tripathi RP. Indian J Radiol Imaging. 2013 Oct;23(4):354-65. doi: 10.4103/0971-3026.125626. [5] Al Tabaa Y, Bailly C, Kanoun S. FDG-PET/CT in Lymphoma: Where Do We Go Now? Cancers (Basel). 2021 Oct 18;13(20):5222. doi: 10.3390/cancers13205222. [6] Jadvar H. FDG PET in Prostate Cancer. PET Clin. 2009 Apr 1;4(2):155-61. doi: 10.1016/j.cpet.2009.05.002. [7] Han C, Zhu L, Liu X, Ma S, Liu Y, Wang X. Insights Imaging. 2021 Jun 16;12(1):79. doi: 10.1186/s13244-021-01024-3. [8] Bostwick DG, Iczkowski KA, Amin MB, Discigil G, Osborne B. Malignant lymphoma involving the prostate: report of 62 cases. Cancer 1998 Aug 15;83(4):732-8. doi: 10.1002/(sici)1097-0142(19980815)83:43.0.co;2-t.

Settembre 9, 2023

Biopsy yields in different PSA density-PI-RADS score cohorts of biopsy-naïve patients with clinically-suspected prostate cancer

PI-RADS score and PSA density provide complementary information which in combination can be helpful in deciding whether biopsy is required in patients with clinically-suspected PCa.

Settembre 9, 2023

MRI comparison of the two most actual classifications of the Mullerian anomalies

References: 1. B.Hamm,P.R.Ros (eds.), Abdominal Imaging, DOI 10.1007/978-3-642-13327-5_179, ©Springer- Heidelberg Verlag Berlin 2013 2. Carrington BM, Hricak H, Nuruddin RN, Secaf E, Laros RK Jr, Hill EC. Müllerian duct anomalies: MR imaging evaluation. Radiology. 1990 Sep;176(3):715-20. doi: 10.1148/radiology.176.3.2202012. PMID: 2202012. 3. Al Najar MS, Al Ryalat NT, Sadaqah JS, Husami RY, Alzoubi KH. MRI Evaluation of Mullerian Duct Anomalies: Practical Classification by the New ASRM System. J Multidiscip Healthc. 2022 Nov 9;15:2579-2589. doi: 10.2147/JMDH.S386936. PMID: 36388626; PMCID: PMC9659481. 4. Ludwin A, Ludwin I. Comparison of the ESHRE-ESGE and ASRM classifications of Müllerian duct anomalies in everyday practice. Hum Reprod. 2015 Mar;30(3):569-80. doi: 10.1093/humrep/deu344. Epub 2014 Dec 22. PMID: 25534461; PMCID: PMC4325671. 5. Ludwin, A., Tudorache, S. and Martins, W.P. (2022), ASRM Müllerian Anomalies Classification 2021: a critical review. Ultrasound Obstet Gynecol, 60: 7-21. https://doi.org/10.1002/uog.24905 6. Zhang Y, Lu W. Lesson Learned from MRI Evaluation of Mullerian Duct Anomalies [Letter]. J Multidiscip Healthc. 2022 Nov 18;15:2667-2668. doi: 10.2147/JMDH.S397426. PMID: 36425877; PMCID: PMC9680959. 7. Grimbizis GF, Gordts S, Di Spiezio Sardo A, Brucker S, De Angelis C, Gergolet M, Li TC, Tanos V, Brölmann H, Gianaroli L, Campo R. The ESHRE-ESGE consensus on the classification of female genital tract congenital anomalies. Gynecol Surg. 2013 Aug;10(3):199-212. doi: 10.1007/s10397-013-0800-x. Epub 2013 Jun 13. PMID: 23894234; PMCID: PMC3718988. 8. Grimbizis, G.F., Di Spiezio Sardo, A., Saravelos, S.H. et al. The Thessaloniki ESHRE/ESGE consensus on diagnosis of female genital anomalies. Gynecol Surg 13, 1–16 (2016). https://doi.org/10.1007/s10397-015-0909-1 9. Ludwin A, Pfeifer SM. Reproductive surgery for müllerian anomalies: a review of progress in the last decade. Fertil Steril. 2019 Sep;112(3):408-416. doi: 10.1016/j.fertnstert.2019.07.005. PMID: 31446900. 10. Knez J, Saridogan E, Van Den Bosch T, Mavrelos D, Ambler G, Jurkovic D. ESHRE/ESGE female genital tract anomalies classification system-the potential impact of discarding arcuate uterus on clinical practice. Hum Reprod. 2018 Apr 1;33(4):600-606. doi: 10.1093/humrep/dey043. PMID: 29514262. 11. Pfeifer SM, Attaran M, Goldstein J, Lindheim SR, Petrozza JC, Rackow BW, Siegelman E, Troiano R, Winter T, Zuckerman A, Ramaiah SD. ASRM müllerian anomalies classification 2021. Fertil Steril. 2021 Nov;116(5):1238-1252. doi: 10.1016/j.fertnstert.2021.09.025. Erratum in: Fertil Steril. 2023 Jun;119(6):1088. PMID: 34756327. 12. Dayana Yankova-Pushkarova , George Hadjidekov, Congenital uterine anomalies. The ESHRE/ESGE classification throught MR image, LAP LAMBERT Academic Publishing, Berlin, Germany, Ref, 2020

Settembre 9, 2023

Incidental findings we don’t want to miss on prostate multiparametric-MRI: a pictorial review

mp-MRI is currently the gold standard imaging method for prostate cancer diagnosis, for detecting focal areas suspicious for clinically significant malignancy that could be considered potential sites for biopsy, while assuming an equally crucial role in prostate cancer regional staging and surveillance. Its widespread usage, combined with a field-of-view that must extend at least in one of the sequences to the level of the aortic bifurcation, allows the detection of both clinically significant and indolent incidental findings, not only in the prostate, but also in the peri-prostatic region, including the remaining pelvic and abdominal organs covered, muscles, bones and vessels. Although many of these findings are benign, some may have clinical implications and represent malignant or potentially life-threatening entities, reinforcing the importance of its recognition. Taken that, and in a context where this exam is often performed for known or strongly suspected prostate cancer, it is particularly crucial for the radiologist to systematically look for and beyond the prostate as our goal is to avoid miss or misdiagnosing in a setting where prompt detection and appropriate follow-up have inevitable implications on clinical management and patient anxiety.

Settembre 9, 2023

Comparison of deep learning algorithms for prostate cancer detection and proposal of a new contrastive learning pre-training approach

Standardization of performaces between DL models allows a comparison between them.

Settembre 9, 2023

Atypical leiomyoma or sarcoma? The great dilemma of the uterine myometrial tumors

1- Sun S, Bonaffini PA, Nougaret S, et al. How to differentiate uterine leiomyosarcoma from leiomyoma with imaging. Diagn Interv Imaging 2019; 100:619-634. 2- Juhasz-Böss I, Gabriel L, Bohle RM, Horn LC, Solomayer E-F,Breitbach G-P. Uterine leiomyosarcoma. Oncol Res Treat 2018; 41: 680-6. 3- Wu T-I,Yen T-C,Lai C-H.Clinical presentation and diagnosis of uterine sarcoma, including imaging. Best Pract Res Clin Obstet Gynaecol 2011; 25: 681-9. 4-Tamai K, Koyama T, Saga T, Morisawa N, Fujimoto K, Mikami Y, et al. The utility of diffusion-weighted MR imaging for differentiating uterine sarcomas from benign leiomyomas. Eur Radiol 2008; 18:723-30. 5- Foti P. V., Tilocca C., Sigona A., Palmucci S., Farina R., Caltabiano R., et al. Benign neoplasms of the uterus: MR imaging of leiomyomas with radiologic-pathologic correlation. WCRJ 2015;2(2): e516. 6-Wilde S, Scott-Barrett S. Radiological appearances of uterine fibroids. Indian J Radiol Imaging. 2009;19(3):222-31. 7-Arleo EK, Schwartz PE, Hui P, McCarthy S. Review of leiomyoma variants. AJR Am J Roentgenol 2015; 205: 912-21. 8-Lall C, Bura V, Lee TK, Bhosale P, Faria SC, Choi J-I, et al. Diffusion-Weighted imaging in hemorrhagic abdominal and pelvic lesions: restricted diffusion can mimic malignancy. Abdom Radiol (NY) 2018; 43: 1772-84. 9-Murase E, Siegelman ES, Outwater EK, Perez-Jaffe LA, Tureck RW. Uterine leiomyomas: histopathologic features, MR imaging findings, differential diagnosis, and treatment. Radiographics 1999; 19: 1179-97. 10-Ueda H, Togashi K, Konishi I, Kataoka ML, Koyama T, Fujiwara T, et al. Unusual appearances of uterine leiomyomas: MR imaging findings and their histopathologic backgrounds. Radiographics 1999; 19 Spec No: S131-45 11- Smith J, Zawaideh JP, Sahin H, Freeman S, Bolton H, Addley HC. Differentiating uterine sarcoma from leiomyoma: BET1T2ER Check! Br J Radiol 2021;94(1125):20201332. 12-Bi Q, Xiao Z, Lv F, Liu Y, Zou C, Shen Y. Utility of clinical parameters and multiparametric MRI as predictive factors for differentiating uterine sarcoma from atypical leiomyoma. Acad Radiol 2018; 25: 993-1002. 13- Skorstad M, Kent A, Lieng M. Preoperative evaluation in women with uterine leiomyosarcoma. A nationwide cohort study. Acta Obstet Gynecol Scand 2016; 95: 1228-34.